what is melanotan: Frequently asked questions

Understand that afamelanotide is the International Nonproprietary Name (INN) for Melanotan 1, assigned when the peptide underwent clinical trial evaluation for EMA approval. Research literature after 2014 increasingly uses 'afamelanotide' when discussing photoprotection studies, EPP treatment outcomes, or regulatory filings, while earlier publications and research-grade suppliers continue using 'Melanotan 1' or 'Melanotan-1'. All three terms describe the same 13-amino-acid peptide. If you're cross-referencing studies, assume nomenclature equivalence unless the paper explicitly describes a structural modification.

Use the peptide as planned. The hyphen doesn't indicate a different compound. Verify the amino acid sequence matches [Nle4, D-Phe7]-α-MSH in the certificate of analysis, confirm the molecular weight is approximately 1646 Da, and check that the supplier is a certified peptide manufacturer. Label formatting inconsistencies are common across research-grade suppliers and don't affect peptide integrity or experimental protocols. If the COA confirms the correct structure, the hyphen is purely cosmetic.

Proceed without modification. Protocols written with hyphenated nomenclature apply identically to non-hyphenated preparations. The peptide's pharmacokinetic properties (30–40 minute half-life, MC1R binding affinity, subcutaneous bioavailability) are independent of label formatting. If the protocol cites afamelanotide or Scenesse as a reference standard, recognize that research-grade Melanotan 1 shares the same core structure, though clinical-grade manufacturing standards differ from research-grade synthesis batches. Dosing, reconstitution, and administration methods remain unchanged.

Consider melanotan-2 (MT2) or combination protocols pairing melanotan-1 with narrow-band UVB phototherapy at sub-erythemal doses. MT2 produces visible pigmentation within 3–7 days due to higher melanogenic potency and MC4R co-activation, but introduces off-target effects (nausea, erections, transient hypertension). The phototherapy combination leverages melanotan-1's constitutive melanogenesis while controlled UV exposure stimulates facultative pathways. The PMLE trials at Leiden University used this approach, achieving pigmentation onset in 5–6 days vs 10–12 days with afamelanotide alone. The UVB dose must remain below MED to avoid the DNA damage the peptide was designed to prevent.

Refrigerate it immediately and use it within 7 days rather than the standard 28-day window. The methionine residue at position 4 is susceptible to oxidative degradation at temperatures above 8°C; while a single 6-hour excursion won't denature the peptide completely, it initiates a degradation cascade that accelerates over time. We've conducted HPLC analysis on temperature-compromised samples. Purity drops from 98.5% to 91–93% after one ambient exposure, with further decline during subsequent storage. For critical experiments, discard the vial and reconstitute fresh peptide.

Yes, but the magnitude and timeline differ significantly. Fitzpatrick I/II individuals have reduced basal melanocyte density and lower constitutive MITF expression compared to phototypes IV–VI, meaning the same MC1R agonist dose produces less absolute melanin synthesis. A University of Arizona dose-response study showed that phototype I subjects required 1.6–2.0× higher cumulative melanotan-1 exposure to achieve equivalent pigmentation depth as phototype III subjects. Pigmentation also fades faster post-treatment in fair-skinned individuals due to higher melanocyte turnover rates. The peptide works via the same mechanism regardless of phototype, but baseline melanocyte biology sets the ceiling for maximal response.

Pigmentation persists for 3–4 weeks after the last dose because melanin remains in keratinocytes as they migrate through the epidermis to the stratum corneum. Once receptor stimulation stops, no new melanin is synthesised, and the tan fades at the rate of natural epidermal turnover. Approximately 28 days. Maintenance dosing (0.25–0.5mg once or twice weekly) can sustain pigmentation indefinitely without cumulative receptor desensitisation.

Nausea is the most common side effect of Melanotan-1 peptide, occurring in approximately 10–15% of research subjects at standard dosing. It typically resolves within 2–4 hours and diminishes with repeated administration as tolerance develops. Administering the dose in the evening rather than morning and taking it with food can reduce severity. Persistent nausea beyond 24 hours or nausea accompanied by vomiting, abdominal pain, or other systemic symptoms is not expected and suggests either dose error, product contamination, or an unrelated acute illness.

Yes, but response varies. Fitzpatrick Type I skin has low constitutive melanin and limited melanocyte density, so Melanotan-2 peptide will produce pigmentation. But the shade achieved will be lighter and develop more slowly than in Type III or IV skin. Expect tan development over 10–14 days rather than 5–7 days. The compound cannot synthesise melanin in melanocytes that don't exist, so individuals with complete albinism (OCA1A, total absence of functional tyrosinase) will not tan regardless of dose.

Consult a dermatologist before considering Melanotan-1 peptide. While the compound was originally developed for melanoma prevention through photoprotection, stimulating melanocytes in individuals with existing dysplastic nevi or melanoma history introduces theoretical risk. Clinical trials excluded patients with active melanoma, and long-term safety data in high-risk populations remains limited. The darkening of existing moles is a documented side effect. Any change in mole appearance, symmetry, or border regularity warrants immediate dermatological evaluation.

Source pharmaceutical-grade material from a regulated supplier with third-party HPLC verification. Cosmetic use remains off-label in most jurisdictions, and product quality varies dramatically in unregulated markets. Peptides synthesised without proper purification can contain deletion sequences, oxidised residues, or bacterial endotoxins that alter both efficacy and safety. Expect gradual pigmentation over 4–6 weeks at research-referenced dosing (0.16 mg/kg subcutaneously). Do not expect immediate darkening. The mechanism requires cumulative melanocyte stimulation.

Nausea is MC4R-mediated and occurs in approximately 30–40% of users during initial doses. It peaks 30–60 minutes post-injection and resolves within 2–4 hours. Mitigation strategies: inject in the evening before sleep (so nausea occurs during rest), reduce dose to 0.1–0.25mg and titrate upward slowly, or take the injection with a small amount of food. The effect diminishes with repeated dosing as receptor adaptation occurs. Most users report nausea resolution by day 5–7 of a loading protocol.

Melanin production increases in all melanocytes when MC1R is activated, meaning existing moles, birthmarks, and pigmented lesions will darken alongside baseline skin tone. This is an expected pharmacological effect, not an adverse event, but it complicates visual monitoring for melanoma in individuals with numerous or atypical nevi. Dermatology research emphasizes baseline photographic documentation before melanocortin agonist exposure so that new lesions can be distinguished from darkening of pre-existing ones. Melanotan-2 does not create new moles. It amplifies pigmentation in melanocytes already present.

Improper reconstitution. Using non-bacteriostatic water, incorrect dilution ratios, or vigorous shaking. Can denature the peptide structure or introduce microbial contamination. Melanotan-2 is supplied as lyophilized powder and must be reconstituted with bacteriostatic water at the ratio specified by the supplier (commonly 1–2 mL per vial containing 10mg peptide). The vial should be gently swirled, never shaken, to dissolve the powder without disrupting the cyclic peptide bonds. Once reconstituted, the solution must be refrigerated at 2–8°C and used within 28 days. Any cloudiness, discoloration, or particulate matter indicates degradation. Discard and reconstitute a fresh vial.

Nausea following melanotan-2 administration is common and traces to melanocortin receptor activation in the area postrema. The brainstem region responsible for triggering vomiting in response to circulating emetic signals. This effect is dose-dependent and typically resolves within 1–2 hours post-injection. Research models mitigate this by reducing dose, administering the injection before sleep (when nausea is less disruptive), or splitting doses across the day. The nausea does not indicate peptide degradation or contamination. It reflects on-target MC4R activity in the central nervous system.

Discard the vial immediately. Do not attempt to re-refrigerate and use. Peptide bond hydrolysis and methionine oxidation occur within 4–6 hours at 20–25°C, and this degradation is irreversible. HPLC analysis of temperature-compromised Melanotan 1 shows fragmentation peaks corresponding to cleavage between Ser-1 and Tyr-2, producing inactive peptide fragments that cannot bind MC1R. Visual inspection is insufficient. The solution may remain clear while peptide integrity is completely lost. For labs conducting dose-response studies, using degraded peptide introduces unquantifiable variability that invalidates concentration-response curves. The cost of repeating failed experiments far exceeds the cost of discarding a compromised vial.

Uneven pigmentation typically reflects inconsistent dosing, variable melanocyte density across body regions, or pre-existing pigmentation patterns like freckles and moles. MC1R expression isn't uniform. Areas with higher melanocyte concentration (face, arms, existing pigmented lesions) darken faster than regions with lower density. Research protocols often include a loading phase with daily administration to establish baseline melanin synthesis before transitioning to maintenance dosing, which reduces the patchy appearance. Individuals with extensive freckling or dysplastic nevi may experience preferential darkening of these lesions, which is why dermatological assessment is recommended before initiating research involving melanotan-2.

Verify reconstitution protocol first. Specifically bacteriostatic water volume and mixing technique. Melanotan 1 requires gentle swirling (never shaking) to dissolve, and vigorous agitation creates foam that denatures peptide at the air-liquid interface. Inconsistent reconstitution volumes (e.g., 1 mL versus 2 mL) double the effective dose concentration, which shifts the entire dose-response curve. Second, confirm storage temperature with a calibrated thermometer. Standard refrigerators often cycle between 1°C and 9°C, and repeated excursions above 8°C cause cumulative degradation even without full temperature failure. Third, check for freeze-thaw cycles if using aliquots: each freeze-thaw reduces activity by approximately 10–15% due to ice crystal-induced mechanical stress on peptide structure. For reproducible melanogenesis assays, prepare single-use aliquots at the start of each experiment rather than repeated draws from a shared vial.

This indicates observer-dependent visual assessment is detecting erythema (redness from vascular changes) or superficial desquamation artifacts rather than true melanogenesis. Melanin increases must be quantified objectively: reflectance spectroscopy at 650 nm wavelength measures melanin specifically, while visual assessment conflates pigmentation with inflammation. Research published in Photodermatology, Photoimmunology & Photomedicine demonstrated that subjective visual grading of pigmentation correlated only 60% with objective melanin density measurements in MC1R agonist studies. The solution is dual-endpoint assessment: pair visual grading (for subjective appearance relevant to cosmetic applications) with spectrophotometric or histological melanin quantification (for mechanistic validation). True melanogenesis produces dose-dependent increases in both eumelanin content per melanocyte and melanocyte dendricity (the number of melanin-delivering processes extending to surrounding keratinocytes).

Maintenance dosing becomes necessary after the loading phase. Melanin naturally degrades as melanin-laden keratinocytes reach the stratum corneum and desquamate. The baseline keratinocyte turnover rate is approximately 28 days, meaning pharmacologically induced pigmentation fades at this rate without continued MC1R stimulation. Research protocols investigating long-term photoprotection typically employ loading doses 3 times weekly for 3 weeks, followed by maintenance doses once or twice weekly for the duration of the study. Plasma levels of Melanotan 1 peak at 60–90 minutes post-injection and return to baseline within 4–6 hours, so the peptide itself does not accumulate. The cumulative effect comes from sustained MITF upregulation maintaining elevated tyrosinase expression. Dose intervals shorter than 48 hours provide no additional benefit because melanin synthesis from tyrosine to mature eumelanin polymer requires 48–72 hours for complete pigment deposition.